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1  | INTRODUC TION
Resistant hypertension is defined as blood pressure (BP) above treat-
ment goals despite the concurrent use of 3 or more antihypertensive 
drugs, including diuretics, and also includes patients whose BP 
achieves target values on ≥4 antihypertensive drugs.1 The prev-
alence of resistant hypertension is between 12% and 18% of the 
population.1-3 It is more highly associated with high-risk conditions 
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Abstract
Resistant hypertension was defined according to the 2008 scientific statement as 
office blood pressure ≥ 140/90 mm Hg and the 2018 scientific statement as office 
blood pressure ≥ 130/80 mm Hg. We investigated the prognostic significance of 
lowered blood pressure threshold for defining resistant hypertension in the 2018 
American Heart Association scientific statement compared with that in the 2008 
scientific statement. The participants of this prospective cohort were enrolled from 
December 2013 to November 2018. Major adverse cardiovascular events (MACEs) 
were defined as a composite of cardiovascular death, non-fatal myocardial infarc-
tion, non-fatal stroke, and heart failure hospitalization. Renal event was defined as 
a ≥ 50% decline in estimated glomerular filtration rate or progression to end-stage 
renal disease. A total of 206 patients among 2018 (10.2%) were diagnosed with re-
sistant hypertension by the previous definition (≥140/90 mm Hg), and 276 patients 
among 2011 (13.7%) were diagnosed with resistant hypertension by the updated 
definition (≥130/80 mm Hg). During a median follow-up of 4.5 years, 33 MACEs (3.7 
per 1000 patient-years) and 164 renal events (19.9 per 1000 patient-years) occurred 
in the study population. Treatment-resistant hypertension groups had a higher inci-
dence rate of MACEs and renal events than the control groups. In multivariate Cox 
proportional hazards regression analysis, resistant hypertension by both definitions 
was significantly associated with increased risk of MACE and renal event. Both the 
previous and updated definitions of resistant hypertension were significant predic-
tors of MACEs and renal events. This finding supports the adoption of the updated 
criteria for resistant hypertension in clinical practice.
2094  |     CHUN et al.
such as diabetes mellitus (DM) and chronic kidney disease (CKD).4,5 
Resistant hypertension is associated with increased risk for end-
stage renal disease, cardiovascular events (CVEs), and mortality.1,6 
Therefore, correct identification and BP control in these high-risk 
participants are imperative. Recently, the American College of 
Cardiology (ACC) and the American Heart Association (AHA) re-
defined hypertension as BP above 130/80 mm Hg.7 Based on this 
new threshold, the 2018 scientific statement from the AHA lowered 
the BP threshold of resistant hypertension from above 140/90 mm 
Hg, based on the 2008 AHA definition, to above 130/80 mm Hg.1,8 
Since an important objective for diagnosing resistant hypertension 
is to identify a subset of high-risk hypertensive participants, it is 
necessary to determine how much lowering of the BP threshold in-
fluences the risk profile of resistant hypertension. A previous study 
suggested that early and more intensive BP control contributes to 
better target organ protection and cardiovascular prevention in 
Asian populations.9 However, it is unclear how lowering of the BP 
threshold changes the risks for CVEs and adverse renal outcomes, 
particularly in high-risk hypertension patients. In a pooled analysis 
of patient-level data of the Systolic Blood Pressure Intervention Trial 
and Action to Control Cardiovascular Risk in Diabetes trial, no sig-
nificant difference was found in the risk for CVEs for treatment-re-
sistant hypertension based on the 2018 AHA definition versus the 
2008 definition when the exposure time was ≥1.5 years.10 However, 
these data were limited by not performing ambulatory blood pres-
sure monitoring (ABPM) in the majority of the study participants. As 
white-coat resistance is highly prevalent, the 2018 AHA statement 
and the 2018 European Society of Cardiology/European Society of 
Hypertension guidelines recommend the use of out-of-office BP 
measurements to rule out white-coat hypertension before diagnos-
ing resistant hypertension, and detection of masked uncontrolled 
hypertension, which is highly prevalent in Asian hypertensive pop-
ulations, is also important.1,11-13 Therefore, the objective of this 
study was to compare the prognostic significance between the 2018 
and 2008 definitions of apparent treatment-resistant hypertension 
(aTRH), confirmed by both office BP and ABPM, in a prospective 
cohort of high-risk hypertensive patients without prior history of 
symptomatic cardiovascular disease (CVD) at baseline.
2  | METHODS
2.1 | Study population
The participants of this prospective cohort were recruited from a 
South Korean government-sponsored prospective cohort study 
(Cardiovascular and Metabolic Disease Etiology Research Center-
High Risk Cohort [CMERC-HI], clinicaltrials.gov: NCT02003781) 
that targeted those with high cardiovascular (CV) risk. The inclusion 
criteria of the CMERC-HI have been published previously (Methods 
in Supporting Information).14,15 According to the criteria, 3270 con-
secutive patients were enrolled in the cohort study from December 
2013 to November 2018. We investigated the effect of resistant 
hypertension on future CV outcomes among patients treated with 
antihypertensive agents. We excluded patients with established 
symptomatic CVD (history of ischemic heart disease, ischemic 
or hemorrhagic stroke, heart failure [HF], and atrial fibrillation), 
CKD stage 5 (estimated glomerular filtration rate (eGFR) <15 mL/
min/1.73 m2), and end-stage renal disease (ESRD) requiring regular 
dialysis therapy and those who received kidney transplant. ABPM 
was performed at baseline in 1666 (82.1%) of the remaining 2029 
participants.
For participants classified according to previous diagnostic 
criteria, aTRH (hereafter, aTRHprior) was defined according to the 
2008 AHA scientific statement as having elevated office systolic 
BP ≥ 140 or diastolic BP ≥ 90 mm Hg with elevated daytime aver-
age systolic BP ≥ 135 or diastolic BP ≥ 85 mm Hg on ABPM with 
use of 3 antihypertensive drugs, including a diuretic, at the time 
of enrollment; or use of ≥4 antihypertensive drugs at the time 
of enrollment regardless of uncontrolled or controlled office BP 
and/or ambulatory BP (ABP). The updated diagnostic criteria for 
aTRH according to the 2018 AHA scientific statement (hereaf-
ter, aTRHupdated) were defined as office systolic BP ≥ 130 or di-
astolic BP ≥ 80 mm Hg with daytime average systolic BP ≥ 130 
or diastolic BP ≥ 80 mm Hg on ABPM with the same antihyper-
tensive treatment criteria as aTRHprior. If the participants who 
used 3 antihypertensive drugs had uncontrolled office BP but 
did not have available ABPM data, they were excluded from the 
analysis because we could not determine whether it was white-
coat resistance (11 patients from the prior definition, 18 patients 
from the updated definition). The rest of the study participants 
according to each definition were categorized as control groups. 
Finally, we analyzed those who satisfied the diagnostic criteria for 
aTRH put forth by the prior AHA scientific statement (N = 2018; 
Figure 1) and the updated 2018 AHA scientific statement defini-
tion (N = 2011; Figure 1).7,8 The CMERC-HI study protocol was 
approved by the Institutional Review Boards of Yonsei University 
Health System (institutional review board number: 4-2013-0581). 
Written informed consent was provided by all participants.
2.2 | BP measurement
Office BP was obtained using a validated automatic device (HEM 
7080-IC; Omron), which was programmed to automatically measure 
the sitting BP of a person at 5, 7, and 9 minutes.16,17 After positioning 
the subject in a sitting position with the right arm supported at heart 
level and setting the device, a trained nurse left the participants 
alone in the examination room. After a 5-minute rest, automatic 
BP measurements at 2-minute intervals were obtained. After three 
measurements, the trained nurse recorded the BP data. The mean of 
the three BP readings was used as the office BP. Twenty-four-hour 
ABP readings were obtained using the Takeda TM-2430 instrument 
(A&D Medical, Tokyo, Japan), with readings taken every 30 minutes. 
We defined an adequate ABP recording as having at least 70% of 
the expected measurements, and at least 14 measurements during 
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the day and 7 measurements at night.18 Daytime and nighttime pe-
riods were defined according to the information provided in partici-
pants’ diaries. Ambulatory BP readings were averaged for 24-hour, 
daytime, and nighttime values.15 If the time difference between of-
fice BP and ABP measurements exceeded 3 months, only office BP 
measurements were included in the analyses. The mean time differ-
ence between office BP and ABP measurements was 5 (±40) days.
2.3 | Outcomes
The primary outcome was first occurrence of major adverse cardio-
vascular events (MACEs), which were a composite of non-fatal myo-
cardial infarction, non-fatal stroke, hospitalization for HF, and CV 
mortality. The secondary outcomes were non-fatal CVE (non-fatal 
myocardial infarction, non-fatal stroke, and hospitalization for HF), 
each component event of a composite outcome, and renal event.
HF hospitalization was defined as an event that meets all of the 
following criteria: (a) requiring hospitalization due to clinical mani-
festations of HF (eg, dyspnea, orthopnea, paroxysmal nocturnal dys-
pnea, edema, pulmonary basilar crackles, jugular venous distension, 
third heart sound or gallop rhythm, radiological evidence of worsen-
ing HF) and additional therapy including oral or intravenous diuretic, 
inotrope, or vasodilator therapy, and (b) elevated serum biomarker 
(N-terminal pro-brain natriuretic peptide) level > 300 ng/L (if there 
was an evidence that left ventricular ejection fraction was <40% in 
any imaging modality including echocardiography, myocardial per-
fusion scan, or cardiac magnetic resonance imaging, a threshold of 
600 ng/L was used).
Non-fatal myocardial infarction was defined if there was evi-
dence of myocardial necrosis in a clinical setting consistent with 
myocardial ischemia. It was defined if the patient was admitted for 
myocardial infarction with at least 2 of 3 criteria as follows: (a) symp-
tom of ischemic chest pain, (b) elevation of cardiac enzyme level, 
and (c) significant luminal narrowing of coronary artery confirmed by 
any imaging modality including angiography or CT scan. Stroke was 
defined as a composite of hemorrhagic stroke and ischemic stroke 
requiring hospitalization due to new onset neurologic deficit and 
correlating lesions found in brain imaging studies.
The cause of death was determined by the principal condition 
that caused the death, not the immediate mode of death. The infor-
mation was obtained from medical records and yearly telephone sur-
veys. CV death was defined as death due to HF, stroke, or myocardial 
infarction. Non-CV death was defined as any death not covered by 
CV death. Examples of non-CV death are pulmonary causes, renal 
causes, infection (including sepsis), malignancy, accidental trauma, 
non-CV organ failure (eg, hepatic failure), and non-CV surgery.
Renal event was defined as follows: a decrease in eGFR of 50% 
or more compared with baseline to less than 60 mL/min/1.73 m2 in 
participants who had eGFR ≥ 60 mL/min/1.73 m2 at baseline, and a 
decrease in eGFR of 50% or more compared with baseline or pro-
gression to ESRD requiring either prolonged dialysis or kidney trans-
plantation in participants who had eGFR < 60 mL/min/1.73 m2 at 
baseline. Serum creatinine was measured with an isotope-dilution 
mass spectrometry traceable method, and the eGFR was calculated 
from the serum creatinine level by using the CKD Epidemiology 
Collaboration equation19 Both clinical and renal events were ana-
lyzed by three independent investigators. Events that were agreed 
upon by all three investigators were deemed as clinical and renal 
outcomes.
2.4 | Statistical analysis
All continuous data are presented as mean ± standard deviation, 
and categorical data are expressed as numbers and percentages for 
each group. In case of serious deviation from normal distribution, 
median and interquartile range and the Wilcoxon rank-sum test were 
used. The effects of aTRH according to each definition on clinical 
events were analyzed with multivariate Cox proportional hazards 
models, which were adjusted for age, sex, current smoking, DM, and 
eGFR. To incorporate all events which comprise MACEs, we used 
F I G U R E  1   Flowchart of study 
participants
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the Prentice, Williams, and Peterson model analyses in Cox propor-
tional hazards analysis for MACE.20 Harrell's concordance index was 
used to assess the predictive accuracy of the prognostic models. To 
compare the values of Cox regression models in outcome predic-
tion, comparisons of receiver operating characteristic (ROC) curves 
and pairwise comparisons were applied. The Cox proportional haz-
ards models used to show the ROC curves were analyzed within the 
participants classified by the updated definition (N = 2011), and we 
used CKD (≥stage 3) as a binary covariate instead of eGFR level in 
these analyses. Areas under the ROC curves (AUCs) were calculated 
and compared using a method described by DeLong et al21 Survival 
rates were estimated using the Kaplan-Meier survival method, and 
differences were analyzed by a log-rank test. All tests were two-
sided, and statistical significance was defined as P < .05. All statis-
tical analyses were performed with R statistical software (version 
3.6.3; R Foundation for Statistical Computing).
3  | RESULTS
3.1 | Baseline characteristics
Table 1 outlines the baseline characteristics of the study participants 
who were divided according to the prior/updated definition of resist-
ant hypertension. A total of 206 patients among 2018 participants 
(10.2%) were diagnosed with aTRHprior, and a total of 276 patients 
among 2011 participants (13.7%) were diagnosed with aTRHupdated 
(Figure 2A). When defined only with office BP without ABPM, 230 
(11.3%) and 318 (15.7%) among 2029 participants were diagnosed 
with resistant hypertension by using the prior and updated defini-
tions, respectively. Patients with aTRH had higher body mass index 
(BMI) and waist and hip circumference, as well as higher proportion 
of CKD (≥stage 3) (Table 1). As expected, all BP measurements, ex-
cept all-day and daytime diastolic BP in aTRHprior, were higher, and 
eGFR levels were significantly lower in the aTRH groups than in 
the control groups. Patients used a median of 4 antihypertensive 
drugs in both aTRH groups, and the proportion of participants tak-
ing 4 or more drugs were 77.6% and 57.4% in aTRHprior and aTRHup-
dated, respectively (Table S1), whereas the rest of the participants 
in each aTRH group were uncontrolled hypertensive patients who 
were taking 3 antihypertensive drugs (17.5% in aTRHprior, 38.4% in 
aTRHupdated). All classes of antihypertensives were prescribed more 
frequently in the aTRH groups than in the control groups, except for 
angiotensin-converting enzyme inhibitors (Table 1).
3.2 | CV and renal outcomes during follow-up
After a median follow-up of 4.5 years (interquartile range: 3.2-
5.4 years, maximum of 6.3 years), which corresponded to 8740 
patient-years (PY) of follow-up, 33 MACEs occurred (crude event 
rate: 3.9 per 1000 PY) with 30 non-fatal CVEs (crude event rate: 
3.5 per 1000 PY, 14 HF hospitalization, 6 MI, and 11 strokes). Three 
patients died from CV causes (0.3 per 1000 PY). A total of 164 renal 
events occurred (crude event rate: 19.8 per 1000 PY, 84 patients 
started dialysis, 19 patients received kidney transplants). When 
compared with control participants, aTRHprior patients had a higher 
event rate of HF hospitalization, and aTRHupdated patients showed a 
trend toward higher event rate of HF hospitalization (Table 2). When 
compared with each control subject, aTRHprior and aTRHupdated pa-
tients had higher rates of renal event, non-fatal CVE, and MACE 
(Table 2). This trend was also observed when we defined aTRH with 
office BP or ABPM alone (Tables S2 and S3). We evaluated the as-
sociation of aTRH with MACE by Kaplan-Meier survival analysis. 
Both aTRHprior and aTRHupdated had a higher risk for MACE (log-rank 
P < .0001,.00075, respectively; Figure 2B,C) and renal event (both 
log-rank P < .0001; Figure 3A,B). In multivariate Cox proportional 
hazards analysis after adjustment for age, sex, DM, eGFR, and cur-
rent smoking (Table 3), both aTRHprior and aTRHupdated showed sig-
nificantly higher risk for HF hospitalization, renal event, non-fatal 
CVE, and MACE. When analyzed with office BP alone, a significantly 
higher risk for non-fatal CVE and MACE was still found in the aTRH 
groups than in the control groups. However, the difference in the risk 
for renal event was not statistically significant for either definition of 
aTRH with office BP alone (Table S4). Moreover, when analyzed only 
with ABPM, a significantly higher risk for HF hospitalization, non-
fatal CVE, and MACE, but not for renal event, was still observed for 
either definition of aTRH (Table S5).
To investigate the difference of the predictive value for MACE 
between aTRHprior and aTRHupdated, we analyzed the ROC curves 
from each definition (Figure 4A). No significant difference was found 
in AUCs of the 2 multivariate Cox proportional hazards models with 
both aTRHprior and aTRHupdated for 4-year MACE-free survival. We 
also compared the ROC curves for renal event, and we obtained a 
similar result that no significant difference was observed in AUCs 
of the 2 models with both aTRH for 4-year renal event-free survival 
(Figure 4B). In addition, when we analyzed the predictive values of 
each aTRH for the outcomes across various subgroups, risk of both 
aTRH for MACE was not significantly different across various sub-
groups (Figure S1).
4  | DISCUSSION
The key findings from this study were as follows. First, despite the 
increased prevalence of resistant hypertension defined according to 
the updated statement (aTRHupdated), the increased risk for MACE 
was still significant compared with controlled hypertensive partici-
pants without any significant interaction for age, sex, BMI, presence 
of DM, and presence of CKD. Moreover, no significant difference 
was found in the accuracy for predicting MACE. Second, both 
aTRHprior and aTRHupdated were significant risk factors for predict-
ing major renal end points without significant difference in accuracy. 
Recent changes in both the threshold for hypertension diagnosis 
and the target BP put forth by the 2017 ACC/AHA guideline have 
led to changes in the definition of resistant hypertension in 2018. 
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TA B L E  1   Baseline characteristics
aTRHprior 
(≥140/90 mm Hg) Control
P-value
aTRHupdated 
(≥130/80 mm Hg) Control
P-value(N = 206) (N = 1812) (N = 276) (N = 1735)
Clinical demographics
Age (y) 61.5 ± 11.2 60.7 ± 11.1 .353 61.3 ± 10.9 60.7 ± 11.2 .439
Male sex, n (%) 88 (42.7%) 836 (46.1%) .390 116 (42.0%) 806 (46.5%) .192
BMI (kg/m2) 27.3 ± 4.1 25.5 ± 3.5 <.001 27.2 ± 4.0 25.4 ± 3.5 <.001
Waist circumference (cm) 92.0 ± 11.0 87.9 ± 9.4 <.001 92.1 ± 11.0 87.7 ± 9.3 <.001
Hip circumference (cm) 97.9 ± 10.1 94.9 ± 6.4 <.001 97.8 ± 9.4 94.8 ± 6.3 <.001
Diabetes, n (%) 104 (50.5%) 795 (43.9%) .084 132 (47.8%) 763 (44.0%) .262
CKD (≥stage 3), n (%) 76 (36.9%) 489 (27.0%) .004 93 (33.7%) 472 (27.2%) .031
Office BP measurement
Office SBP (mm Hg) 135.8 ± 19.6 125.8 ± 14.7 <.001 134.4 ± 17.6 125.6 ± 14.8 <.001
Office DBP (mm Hg) 76.8 ± 10.8 75.3 ± 9.5 .057 77.5 ± 10.0 75.1 ± 9.6 <.001
Pulse rate (bpm) 64.8 ± 11.1 69.5 ± 11.0 <.001 66.3 ± 11.7 69.5 ± 10.9 <.001
ABPM
All-day SBP (mm Hg) 134.8 ± 15.2 128.5 ± 13.7 <.001 133.8 ± 13.9 128.4 ± 13.9 <.001
All-day DBP (mm Hg) 78.1 ± 7.9 77.2 ± 8.2 .179 78.6 ± 7.7 77.1 ± 8.2 .009
Day time SBP (mm Hg) 139.1 ± 15.2 133.4 ± 14.1 <.001 138.5 ± 13.9 133.2 ± 14.3 <.001
Day time DBP (mm Hg) 81.1 ± 8.3 80.4 ± 8.3 .323 81.8 ± 8.2 80.2 ± 8.3 .008
Night time SBP (mm Hg) 127.2 ± 18.1 119.4 ± 16.0 <.001 125.2 ± 16.9 119.4 ± 16.2 <.001
Night time DBP (mm Hg) 72.9 ± 9.7 71.2 ± 8.6 .024 72.8 ± 9.3 71.2 ± 8.6 .007
Antihypertensive drugs
No. of drugs 4 [4-4] 2 [1-2] <.001 4 [3-4] 2 [1-2] <.001
RAS inhibitors 198 (96.1%) 1440 (79.5%) <.001 260 (94.2%) 1371 (79.0%) <.001
ARBs 185 (89.8%) 1361 (75.1%) <.001 244 (88.4%) 1295 (74.6%) <.001
ACE inhibitors 13 (6.3%) 95 (5.2%) .630 16 (5.8%) 92 (5.3%) .846
CCBs 195 (94.7%) 983 (54.2%) <.001 255 (92.4%) 917 (52.9%) <.001
Beta-blockers 179 (86.9%) 368 (20.3%) <.001 195 (70.7%) 351 (20.2%) <.001
Diuretics 199 (96.6%) 377 (20.8%) <.001 269 (97.5%) 300 (17.3%) <.001
Spironolactone 11 (5.3%) 27 (1.5%) <.001 14 (5.1%) 24 (1.4%) <.001
Thiazidea  146 (70.9%) 316 (17.4%) <.001 202 (73.2%) 253 (14.6%) <.001
Minoxidil 8 (3.9%) 0 (0.0%) <.001 8 (2.9%) 0 (0.0%) <.001
Alpha-blockers 31 (15.0%) 29 (1.6%) <.001 32 (11.6%) 28 (1.6%) <.001
Statins 116 (56.3%) 1071 (59.1%) .485 160 (58.0%) 1022 (58.9%) .820
Aspirin 69 (33.5%) 500 (27.6%) .089 92 (33.3%) 475 (27.4%) .049
Laboratory findings
Hemoglobin, g/dL 13.3 ± 1.9 13.7 ± 1.7 .005 13.5 ± 1.9 13.7 ± 1.7 .107
BUN (mg/dL) 22.9 ± 11.0 19.4 ± 9.1 <.001 22.2 ± 10.9 19.4 ± 9.1 <.001
Creatinine (mg/dL) 1.3 ± 0.8 1.1 ± 0.6 <.001 1.3 ± 0.8 1.1 ± 0.6 <.001
eGFR (mL/min/1.73 m2) 62.1 ± 23.7 69.5 ± 21.5 <.001 63.7 ± 23.8 69.5 ± 21.5 <.001
Total cholesterol (mg/dL) 176.0 ± 41.7 171.8 ± 36.6 .173 174.6 ± 41.1 171.9 ± 36.6 .301
Triglyceride (mg/dL) 156.9 ± 83.7 144.5 ± 86.2 .061 155.8 ± 82.5 144.3 ± 86.6 .048
HDL cholesterol (mg/dL) 47.0 ± 12.5 49.4 ± 12.9 .015 47.3 ± 12.5 49.5 ± 12.9 .012
LDL cholesterol (mg/dL) 94.2 ± 28.3 94.0 ± 31.3 .910 93.8 ± 28.6 94.1 ± 31.3 .905
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; aTRH, apparent treatment-resistant hypertension; BMI, 
body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; RAS, renin-angiotensin system; SBP, systolic blood pressure.
aThiazide includes thiazides and thiazide-like drugs (indapamide, chlorthalidone). 
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F I G U R E  2   Proportion of apparent treatment-resistant hypertension and cardiovascular outcomes. The proportion of participants with 
resistant hypertension was higher by the updated definition than by the prior definition in the total participants (A). The participants who 
were taking 3 antihypertensive drugs were divided into resistant hypertension by each definition, and those who were taking 4 or more 
antihypertensive drugs were classified as resistant hypertension regardless of their blood pressure. Kaplan-Meier survival curves for major 
adverse cardiovascular events according to resistant hypertension defined by the prior (B) and updated criteria (C) showed that they all had 
a significantly higher risk for adverse cardiovascular events. BP, blood pressure; aTRH, apparent treatment-resistant hypertension








(N = 1735) P-value*
HF hospitalization 5 (5.2) 9 (1.2) .043 6 (4.6) 8 (1.1) .065
Stroke (non-fatal) 3 (3.1) 7 (0.9) .229 3 (2.3) 7 (0.9) .325
MI (non-fatal) 2 (2.1) 4 (0.5) .296 2 (1.5) 4 (0.5) .373
Renal event 34 (35.0) 130 (16.8) <.001 42 (32.3) 122 (16.5) .001
Non-fatal CVE 10 (10.3) 20 (2.6) .020 11 (8.5) 19 (2.6) .010
CV death 1 (1.0) 2 (0.3) .461 1 (0.8) 2 (0.3) .530
MACE 11 (11.3) 22 (2.8) .007 12 (9.2) 21 (2.8) .019
Note: Described as number of events (incidence rate, per 1000 patient-years of follow-up).
Abbreviations: CV, cardiovascular; CVE, cardiovascular event; HF, heart failure; MI, myocardial infarction. Other abbreviations are defined in Table 1.
*Comparison was performed for incidence rate of the event. 
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However, whether or not a lower threshold for diagnosing resist-
ant hypertension would change the degree of risk for resistant hy-
pertension as a high-risk factor for CVD was not clear. The present 
results showed that lowering the threshold could identify more par-
ticipants with high-risk resistant hypertension without sacrificing its 
predictive value for CV and renal end points.
To date, observational studies using the 2008 criteria showed 
that patients with resistant hypertension are at higher risk for poor 
outcomes compared with patients without resistant hyperten-
sion.6,22-24 In a retrospective study of over 200 000 patients with hy-
pertension, those with resistant hypertension have 47% higher risk 
for combined outcomes of death, HF, stroke, myocardial infarction, 
or CKD over a median follow-up of 3.8 years.22 In this study, the dif-
ference in the incidence of composite outcomes was driven largely by 
a higher risk for the development of CKD events.22 In another study 
of over 400 000 patients, patients with resistant hypertension have 
46% increased risk of HF, 32% increased risk of developing ESRD, 
24% increased risk of an ischemic heart event, 14% increased risk 
of stroke, and 6% increased risk of death.6 However, these studies 
applied the 2008 criteria for the diagnosis of resistant hypertension, 
and no studies have been conducted to analyze the prognosis of 
resistant hypertension based on the 2018 definition. The present 
study is the first to show that aTRH by both criteria had a higher risk 
for combined outcomes of HF, stroke, myocardial infarction, or CV 
death and renal outcomes of CKD progression or initiation of renal 
replacement therapy. In particular, the risk of HF hospitalization 
and renal event was significantly increased with both aTRH criteria. 
These results support the use of the updated criteria for resistant 
hypertension to better identify a subset of hypertensive participants 
who are at high risk. This change has important clinical implications 
as many participants with office BP between 130 and 139 mm Hg 
who would have been considered to have controlled hypertension 
according to the previous definition of resistant hypertension would 
be diagnosed with resistant hypertension and managed accordingly.
Various comorbidities including obesity, DM, and CKD are known 
to be associated with resistant hypertension.25-27 In line with the 
previous reports, our cohort showed that patients with aTRH had 
higher BMI, waist/hip circumference, and higher CKD prevalence 
than controlled hypertensive participants. In subgroup analyses, we 
showed that the risk of both aTRH definitions for MACE was not 
F I G U R E  3   Survival curves for major adverse cardiovascular event. Kaplan-Meier survival curves for renal event according to resistant 
hypertension defined by the prior (A) and updated scientific statements (B). aTRH, apparent treatment-resistant hypertension; MACE, major 
adverse cardiovascular event
TA B L E  3   Multivariate Cox proportional hazards analysis for clinical outcomes according to the resistant hypertension definition
aTRHprior HR [95% CI] C-index P-value aTRHupdated HR [95% CI] C-index P-value
HF hospitalization 3.178 [1.040-9.707] 0.853 .042 3.376 [1.134-10.05] 0.870 .029
Stroke (non-fatal) 2.393 [0.603-9.505] 0.839 .215 1.767 [0.446-7.009] 0.836 .418
MI (non-fatal) 3.226 [0.567-18.37] 0.824 .187 2.332 [0.410-13.28] 0.821 .340
Renal event 1.537 [1.049-2.252] 0.880 .028 1.493 [1.044-2.135] 0.879 .028
Non-fatal CVE 2.651 [1.189-5.909] 0.796 .017 2.314 [1.058-5.063] 0.802 .036
CV death 3.735 [0.284-49.11] 0.976 .316 3.136 [0.233-42.21] 0.975 .389
MACE 2.735 [1.355-5.521] 0.798 .005 2.418 [1.182-4.947] 0.804 .016
Note: Adjusted for age, sex, diabetes, estimated glomerular filtration rate, and current smoking.
Abbreviations: CI, confidence interval; C-index, Harrell's concordance index; HR, hazard ratio. Other abbreviations are defined in Tables 1 and 2.
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significantly different according to older age, sex, DM, obesity, and 
CKD. This is interesting to note considering that aTRH is highly prev-
alent in DM and CKD and is associated with adverse prognosis.4,5
The major CVE rate was relatively lower in the present study 
than in previous studies that analyzed aTRH in other popula-
tions.28,29 The MACE incidence rate in our cohort was 11.3 per 
1000 PY in patients with aTRH according to the previous defini-
tion and 2.8 per 1000 PY in patients with controlled hypertension, 
whereas the overall CVE (including stroke, coronary heart disease, 
and HF) incidence rate was 34.4 per 1000 PY in aTRH patients 
and 16.8 per 1000 PY in patients with controlled hypertension in 
a retrospective study involving a Western population.29 The CVE 
rate may differ according to region, ethnicity, or socioeconomic 
status, even among Asian populations. In a large retrospective 
cohort study of 18 036 patients with resistant hypertension from 
the Cardiovascular Research Network hypertension registry, the 
non-fatal CVE rates were approximately 3.36 events per 1000 PY 
and 28.34 renal events per 1000 PY.22 Our results were consis-
tent with these event rates. The difference in CVE rates may be 
attributed to several reasons. In our study cohort, the proportion of 
patients who were taking ≥ 4 antihypertensive drugs was relatively 
high (Table S1). Moreover, even among these patients taking ≥ 4 
antihypertensive drugs, 54.4% classified by aTRHprior and 23.9% 
classified by aTRHupdated had controlled office BP. The proportion 
of patients with controlled BP was relatively higher in our study 
than in a recent study, which showed that patients with controlled 
BP have lower risks of adverse cardiovascular outcomes related to 
resistant hypertension.28 This may be one of the reasons for the 
relatively lower CVE rate in our study than that in the previous 
study. Additionally, we excluded patients with atrial fibrillation to 
rule out the risk enhancement effect because atrial fibrillation is a 
major risk factor for embolic stroke. Furthermore, because of the 
relatively high prevalence of CKD (29% in the study cohort), renal 
events were 3 times more frequent than MACE in the study popu-
lation. CKD is one of the major risk factors for aTRH, and patients 
with CKD are also prone to progression to ESRD compared with 
patients without CKD.5 Despite these demographical differences 
in our study, significant differences were still found in the adverse 
event rate according to the updated resistant hypertension criteria.
The strength of our study is that we used office BP to diagnose 
resistant hypertension and ruled out white-coat effect with ABPM 
data according to the criteria. Many of the previous studies con-
ducted on resistant hypertension included resistant hypertension 
based on office BP measurement alone, which could lead to mis-
classification of white-coat effect as resistant hypertension. When 
defining resistant hypertension, determining white-coat effect is 
important due to the lower CV risk of participants with white-coat 
effect compared with true sustained uncontrolled hypertension.30 In 
resistant hypertension participants, clinically significant white-coat 
effect has been shown to be present in up to 39% of the participants 
with aTRH by clinic BP measurement.11,31 In the present study, we 
showed that resistant hypertension defined by the prior and up-
dated criteria and by office BP plus ABPM had a significantly higher 
risk for adverse cardiovascular and poor renal outcomes. This com-
parative analysis is the first study to analyze the prognostic effect 
of each definition of resistant hypertension in Asian hypertension 
patients. Our findings have important clinical implications as Asian 
hypertension patients have unique features, including a high preva-
lence of masked hypertension and disrupted BP variability that differ 
from those of other ethnicities.32,33
F I G U R E  4   Comparison of receiver operating characteristic curves for the events. Comparison of receiver operating characteristic (ROC) 
curves for major adverse cardiovascular events (MACE) (A) and renal events (B) at 4 y according to resistant hypertension defined by the 
prior and updated scientific statements. Model 1 is Cox proportional hazards regression model with resistant hypertension by the prior 
definition, and model 2 is by the updated definition. All models were adjusted for age, sex, diabetes, chronic kidney disease (≥stage 3), and 
current smoking. AUC, area under the curve
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4.1 | Study limitations
This study had several limitations. A major limitation of this study 
was that since drug adherence data were not available or evalua-
tion was not performed for secondary hypertension, we could not 
verify that the aTRH participants enrolled in our study all had truly 
resistant hypertension. Second, 1666 out of 2029 participants un-
derwent ABPM. As such, those participants who satisfied the clini-
cal BP criteria for resistant hypertension but did not have available 
ABPM data were excluded from the analysis. However, as only a 
few participants (N = 11 for aTRHprior and N = 18 for aTRHupdated) 
were actually excluded from the analysis, we do not believe that 
this limitation significantly affected the results. Third, we recruited 
a relatively higher number of CKD participants (29% of the study 
cohort), which might have influenced the relatively high incidence 
rate of renal end point compared with other cardiovascular events. 
To eliminate this potential effect on outcome analysis, we excluded 
patients with CKD stage ≥ 5, those who were on dialysis, or those 
who had a history of kidney transplant.
5  | CONCLUSIONS
In a cohort of more than 2000 high-risk hypertension patients with-
out a history of symptomatic atherosclerotic CVD, both the previous 
and updated definitions of resistant hypertension were significant 
predictors of MACEs and renal events. These results support the 
adoption of the updated criteria for resistant hypertension in clinical 
practice, particularly in Asian populations.
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